MTX

Minerals Technologies Announces First Quarter 2024 Conference Call

Retrieved on: 
Friday, March 29, 2024
MTX

NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) announced today that it will release results for its first quarter ended March 31, 2024, on Thursday, April 25, 2024, after the market close.

Key Points: 
  • NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) announced today that it will release results for its first quarter ended March 31, 2024, on Thursday, April 25, 2024, after the market close.
  • The Company will host a conference call on Friday, April 26, 2024, at 11:00 a.m. Eastern Time to discuss these results.

Minerals Technologies Announces Election of Kristina M. Johnson to Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
Master of Science, Electrical engineering, Ohio State University, I Squared Capital, State university system, Education, Duke University, University, Electricity, MTX, Senior, MTI, Mineral, Cisco, State, Stanford University, National academy, Johns Hopkins University, Computer, Government, Management

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today announced that Kristina M. Johnson has been elected to its Board of Directors.

Key Points: 
  • NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today announced that Kristina M. Johnson has been elected to its Board of Directors.
  • “We are excited to welcome Kristina Johnson to our Board,” said Douglas T. Dietrich, Chairman and Chief Executive Officer.
  • She currently serves on the boards of DuPont and Cisco Systems, Inc., and previously served on the Minerals Technologies Inc. Board from 2000 to 2009.
  • Dr. Johnson will begin her service on the MTI Board of Directors on May 13, 2024.

SERB Pharmaceuticals grants exclusive license to M8 Pharmaceuticals, an Acino company, to bring Voraxaze® (Glucarpidase) to cancer patients in Latin America

Retrieved on: 
Wednesday, March 20, 2024
Plasma, Partnership, Risk, Patient, Cancer, National Comprehensive Cancer Network, MTX, Medicine, Hospital

Paris, March 20, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company (“M8”) are collaborating to bring an important drug for cancer patients to Latin America.

Key Points: 
  • Paris, March 20, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company (“M8”) are collaborating to bring an important drug for cancer patients to Latin America.
  • Under the agreement, M8 Pharmaceuticals is licensed to register, market and commercialize SERB’s supportive oncology product Voraxaze® (glucarpidase) in Latin America.
  • Voraxaze® is a carboxypeptidase that reduces toxic plasma methotrexate concentration in adults and children with delayed methotrexate elimination or at risk of methotrexate toxicity.
  • Together, we will ensure this critical medicine becomes accessible to patients across Latin America,” said Antoine Bernasconi, Executive VP and Chief Commercial Officer for EMEA/International at SERB.

UC Berkeley Launches New Molecular Therapeutics Initiative to Accelerate Drug Discovery

Retrieved on: 
Thursday, March 14, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, University, Education, Gene editing, Data science, Drug discovery, Patient, UCB, UC, Artificial intelligence, Chemical biology, Proximity, Cell biology, Cancer, Faculty, Protein, Student, MTI, Doctor of Philosophy, Therapy, Howard Hughes Medical Institute, MTX, University of California, Berkeley, Toxicology, DSM-IV codes, Pharmaceutical industry

The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.

Key Points: 
  • The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.
  • The UC Berkeley Molecular Therapeutics Initiative (MTI) will create a foundational bridge between fundamental research in rare neurological and metabolic diseases and drug discovery to identify and accelerate novel therapeutic modalities into the clinic.
  • “UC Berkeley is an international nucleus for scientific breakthroughs, such as gene editing and immuno-oncology.
  • “In this way, we are not only advancing R&D but also democratizing it by building industry connections for emerging researchers interested in pursuing a biotech career.”
    The UC Berkeley Molecular Therapeutics Initiative (MTI) seeks to accelerate drug discovery efforts by creating therapeutic modalities that overcome challenges in druggability and address unmet medical need.

Minerals Technologies to Present at JP Morgan Industrials Conference

Retrieved on: 
Thursday, March 7, 2024
MTX, Growth, Mineral, Conference

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) announced that its CEO Douglas T. Dietrich will present at the 2024 JP Morgan Industrials Conference focusing on the Company’s strategy, financial results, and growth outlook on Thursday, March 14th, at 7:45 a.m. To listen to webcast please use the following link: JP Morgan Conference Webcast_MTX

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) announced that its CEO Douglas T. Dietrich will present at the 2024 JP Morgan Industrials Conference focusing on the Company’s strategy, financial results, and growth outlook on Thursday, March 14th, at 7:45 a.m. To listen to webcast please use the following link: JP Morgan Conference Webcast_MTX
    In addition, senior management members will attend multiple investor conferences in March.
  • Details and links can be found at MTX Events & Presentations .

Edwin Smith Joins MTX Group as Vice President of Election Solutions

Retrieved on: 
Tuesday, March 5, 2024
MTX, Trust, Certification

DALLAS, March 5, 2024 /PRNewswire/ -- As part of MTX Group's commitment to creating trusted, secure, and accessible election systems, the company announces the addition of Edwin Smith as Vice President of Election Solutions.

Key Points: 
  • DALLAS, March 5, 2024 /PRNewswire/ -- As part of MTX Group's commitment to creating trusted, secure, and accessible election systems, the company announces the addition of Edwin Smith as Vice President of Election Solutions.
  • Ed joins with over two decades of experience in the elections industry and will focus on driving transformation in election office business processes, security, reliability, and innovation.
  • As an experienced leader, Ed previously implemented corporate strategies for market entry, bringing products that span the entire election management cycle to market.
  • He is an expert in election system product management, certification, usability, and security and has supported election deployments on multiple continents.

Memo Therapeutics AG Strengthens Management Team

Retrieved on: 
Monday, February 5, 2024
Leiden University, Bachelor of Science, Supply chain management, CMC, Chemistry, Wageningen University & Research, PPD, Maartje (name), Master of Science, MTX, AbbVie, Barton College, Doctor of Philosophy, Viral, Nursing, Pharmaceutical industry

Ms. Clemmer is an accomplished global clinical research leader with over 20 years of experience directing international clinical operations.

Key Points: 
  • Ms. Clemmer is an accomplished global clinical research leader with over 20 years of experience directing international clinical operations.
  • Ms. Clemmer previously held senior leadership positions at the Contract Research Organizations PRA Health Sciences and PPD.
  • She joins MTx from AM-Pharma, where she was responsible for all drug substance activities including Phase III clinical manufacturing.
  • Eric van den Berg, CEO of MTx, commented: “It is a pleasure to welcome Kristie and Maartje to MTx.

Minerals Technologies Reports Fourth Quarter 2023 Earnings Per Share of $1.22, or $1.28 Excluding Special Items, a Record for Current Quarter

Retrieved on: 
Thursday, February 1, 2024
Biophysical environment, Growth, MTX, BMI, Consumer, Household, Additive, Personal care

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today reported diluted earnings per share of $1.28 for the fourth quarter ended December 31, 2023, excluding special items. Reported diluted earnings per share were $1.22.

Key Points: 
  • For the full year 2023, The Company reported earnings per share of $5.21, excluding special items, compared with $4.88 in the prior year.
  • “Our team delivered a record year of sales, operating income, and earnings per share in 2023.
  • The realignment of our business segments with our key markets and core technologies highlights our balanced portfolio of consumer and industrial businesses.
  • Operating margin excluding special items was 15.0 percent of sales, up 30 basis points over prior year.

Minerals Technologies Declares Quarterly Dividend

Retrieved on: 
Wednesday, January 24, 2024
Mineral, MTX

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today declared a regular quarterly dividend of $0.10 (ten cents) per share on the Company’s common stock.

Key Points: 
  • NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today declared a regular quarterly dividend of $0.10 (ten cents) per share on the Company’s common stock.
  • The dividend is payable on March 7, 2024, to the stockholders of record at the close of business on February 15, 2024.

Dan Osborne Joins MTX Group as Chief Client Officer

Retrieved on: 
Tuesday, January 23, 2024
Local government, Software as a service, Government, Public sector, MTX, Growth

DALLAS, Jan. 23, 2024 /PRNewswire/ -- MTX Group, a premier SaaS implementation partner, is pleased to announce the addition of Dan Osborne as Chief Client Officer.

Key Points: 
  • DALLAS, Jan. 23, 2024 /PRNewswire/ -- MTX Group, a premier SaaS implementation partner, is pleased to announce the addition of Dan Osborne as Chief Client Officer.
  • Prior to joining MTX, Dan led teams for Salesforce in State and Local Government, both on the professional services and licenses side.
  • "As Chief Sales Officer, Dan will drive the goals of our client partners to ensure we are delivering positive outcomes to the communities we serve.
  • I believe in the MTX team and their ability to deliver excellence to our clients," said MTX Chief Client Officer, Dan Osborne.